Interim Management Statement

RNS Number : 0715C

Dechra Pharmaceuticals PLC

06 November 2009

 



Issued by Citigate Dewe Rogerson Ltd, Birmingham

Date: Friday, 6 November 2009

Dechra® Pharmaceuticals PLC

Interim Management Statement

Dechra Pharmaceuticals PLC ("Dechra" or the "Group"), which holds its Annual General Meeting today at 9.00am, publishes its Interim Management Statement covering the period from 1 July 2009 to the date of this announcement as required by the UK Listing Authority Disclosure and Transparency Rules.

The Group has started the financial year in line with management expectations with revenue in the first quarter 5.1% ahead of last year. There have been no material events or transactions during the relevant period and the financial position of the Group remains strong.

The Pharmaceuticals Division has continued to make good progress with first quarter revenue 11.0% higher than the equivalent period last year.  Vetoryl® sales into distributors in the US in the period were US$1.2 million. Sales into veterinary practices in the US are reflecting month on month growth and in September 2009 were almost US$0.5 million, a 25% increase over sales achieved in June 2009.

The Services Division achieved first quarter revenue growth of 3.3%.  National Veterinary Services® maintained its operating margin at the level achieved in the financial year ended 30 June 2009.

The Board remains confident that the Group will continue to make good strategic progress in line with management expectations throughout the remainder of the financial year.

Enquiries:
Ian Page, Chief Executive
Simon Evans, Group Finance Director	Fiona Tooley, Director
Dechra Pharmaceuticals PLC	Citigate Dewe Rogerson
Tel: [phone]	Tel: [phone]
Mobile: + 44 (0)7775 642222 (IP)	Mobile: + 44 (0)7785 703523
or + 44 (0)7775 642220 (SE)
www.dechra.com
[e-mail]

Trademarks appear throughout this release in italics. Dechra and the Dechra 'D' logo are registered Trademarks of Dechra Pharmaceuticals PLC.

 

END

 

 

IMSILFVRLDLEIIA